Chlamydia LPS, Anti-
-
Catalog numberK0911065
-
PricePlease ask
-
Size1X500ug
-
-
DescriptionThis antibody needs to be stored at + 4°C in a fridge short term in a concentrated dilution. Freeze thaw will destroy a percentage in every cycle and should be avoided.
-
GeneBacterial pathogen lipopolysaccharides (LPS) are the major outer surface membrane components present in almost all Gram-negative bacteria and act as extremely strong stimulators of innate or natural immunity in diverse eukaryotic species ranging from insects to humans. LPS consist of a poly- or oligosaccharide region that is anchored in the outer bacterial membrane by a specific carbohydrate lipid moiety termed lipid A. The lipid A component is the primary immunostimulatory center of LPS. With respect to immunoactivation in mammalian systems, the classical group of strongly agonistic (highly endotoxin) forms of LPS has been shown to be comprised of a rather similar set of lipid A types. In addition, several natural or derivative lipid A structures have been identified that display comparatively low or even no immunostimulation for a given mammalian species. Some members of the latter more heterogeneous group are capable of antagonizing the effects of strongly stimulatory LPS/lipid A forms. Agonistic forms of LPS or lipid A trigger numerous physiological immunostimulatory effects in mammalian organisms, but--in higher doses--can also lead to pathological reactions such as the induction of septic shock. Cells of the myeloid lineage have been shown to be the primary cellular sensors for LPS in the mammalian immune system. During the past decade, enormous progress has been obtained in the elucidation of the central LPS/lipid A recognition and signaling system in mammalian phagocytes. According to the current model, the specific cellular recognition of agonistic LPS/lipid A is initialized by the combined extracellular actions of LPS binding protein (LBP), the membrane-bound or soluble forms of CD14 and the newly identified Toll-like receptor 4 (TLR4)*MD-2 complex, leading to the rapid activation of an intracellular signaling network that is highly homologous to the signaling systems of IL-1 and IL-18. The elucidation of structure-activity correlations in LPS and lipid A has not only contributed to a molecular understanding of both immunostimulatory and toxic septic processes, but has also re-animated the development of new pharmacological and immuno-stimulatory strategies for the prevention and therapy of infectious and malignant diseases.
-
Gene target
-
Gene symbolIRF6
-
Short nameChlamydia LPS, Anti-
-
Techniqueanti, antibody to
-
SpeciesChlamydia, Chlamydias
-
Alternative nameChlamydia LPS, antibody to-
-
Alternative techniqueantibodies
-
Diseasechlamydia, Cervix, urethra an eye infection by Chlamydia trachomatis can form inclusion bodies in humans.
-
Gene info
-
Identity
-
Gene
-
Long gene nameinterferon regulatory factor 6
-
Synonyms gene
-
Synonyms gene name
- Van der Woude syndrome
-
Synonyms
-
GenBank acession
-
Locus
-
Discovery year1997-10-16
-
Entrez gene record
-
Pubmed identfication
-
RefSeq identity
-
Classification
- Interferon regulatory factors
-
VEGA ID
MeSH Data
-
Name
-
ConceptScope note: Testing erythrocytes to determine presence or absence of blood-group antigens, testing of serum to determine the presence or absence of antibodies to these antigens, and selecting biocompatible blood by crossmatching samples from the donor against samples from the recipient. Crossmatching is performed prior to transfusion.
-
Tree numbers
- E01.370.225.625.120
- E01.370.225.812.385.120
- E05.200.625.120
- E05.200.812.385.120
- E05.478.594.385.120
-
Qualifiersethics, mortality, psychology, trends, veterinary, history, classification, economics, instrumentation, methods, nursing, standards, adverse effects, statistics & numerical data
